Transcription profiling of human advanced bladder cancer to predict response and survival following chemotherapy in patients

ABSTRACT: BACKGROUND; Cisplatin-containing chemotherapy is the standard of care for patients with locally advanced and metastatic transitional cell carcinoma of the urothelium. The response rate is around 50% and tumor derived molecular prognostic markers are needed for estimation of response and survival. METHODS; Affymetrix GeneChip expression profiling was carried out using tumor material from 30 patients. A set of genes having an expression with high correlation to survival time after chemotherapy was identified. Two of these genes were selected for validation by immunohistochemistry (IHC) in tumor tissue from 149 cisplatin treated patients having complete follow-up data. RESULTS; Fifty-five differentially expressed genes correlated significantly to survival time. Two of these (Emmprin and Su

ORGANISM(S): Homo sapiens

SUBMITTER: Lars Dyrskjøt Andersen 

PROVIDER: E-GEOD-5287 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress